Hangzhou Jiuyuan Genetic Biopharmaceutical Company Description

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices.

The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by radiation therapy, chemotherapy, or postoperative conditions.

It also provides Jifuwei, a fulvestrant injection for advanced breast cancer; Jitansu, a fosaprepitant dimeglumine injection for chemotherapy-induced nausea and vomiting; Jixinfen, a polyethylene glycol-modified human granulocyte colony-stimulating factor injection for neutropenia; Jipailin, a low molecular weight heparin sodium injection for venous thromboembolic diseases; and Yinuojia, an enoxaparin sodium injection for venous thromboembolic diseases.

The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.